A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2
A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 is a paper indexed in ScholarIQ from OpenAlex.
How many citations does A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 have?
A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 has 144 citations in the OpenAlex counts ScholarIQ stores.
When was A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 published?
A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 has 2001 year in the ScholarIQ index.
What is the open-access status of A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2?
A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 has closed oa status in the ScholarIQ index.
What is the DOI of A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2?
The DOI for A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 is on the source record.
What is the PMID of A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2?
The PMID for A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 is on the source record.
What is the OpenAlex record for A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2?
The OpenAlex for A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 is on the source record.